--- title: Link hormones with motor fluctuations nct_id: NCT06582212 phase: NA status: RECRUITING sponsor: University Hospital, Grenoble study_type: INTERVENTIONAL canonical_url: "https://parkinsonspathways.com/trial/NCT06582212" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06582212" last_fetched: "2026-05-10T14:05:54.216Z" source: "Parkinson's Pathways (curated)" --- # Link hormones with motor fluctuations **Goal (in five words):** Link hormones with motor fluctuations **Official Title:** Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers **Trial ID:** [NCT06582212](https://clinicaltrials.gov/study/NCT06582212) ## Key Facts - **Phase:** NA - **Status:** RECRUITING - **Study Type:** INTERVENTIONAL - **Sponsor:** University Hospital, Grenoble - **Target Enrollment:** 100 participants - **Start Date:** 2025-03-12 - **Completion Date:** 2027-03-12 - **Conditions:** Digital Technology, Mobile Application, Motor Fluctuations, Oestrogen, Parkinson Disease - **Interventions:** Mymovesmatter mobile application - **Intervention Types:** DEVICE ## Summary For Families The trial is helping women with Parkinson's see whether hormonal changes are linked to motor fluctuations, so they can better predict and manage symptom ups and downs. Participants use the Mymovesmatter mobile app to track menstrual cycles, hormonal treatments like OCP or IUD, and daily motor symptoms, and the app looks for patterns that could inform timing of levodopa or other treatment and lifestyle discussions with clinicians; the app itself does not change medications. It's enrolling non-menopausal women aged 18 to 56 with Parkinson's diagnosed at least two years ago who are on a stable PD medication regimen and able to give informed consent; post-menopausal women and those with conditions preventing safe participation are excluded. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 56 Years - **Sex:** FEMALE ### Full Criteria ``` Inclusion Criteria: * Non-menopausal women * Diagnosis of PD according to the MDS criteria onset of PD symptoms since at least two years before inclusion * Age 18-56 years * On stable medication regimen for PD for at least two months without foreseen need to modify it within the next three months * With and without OCP or intrauterine devices (IUD Exclusion Criteria: * Post-menopausal women with PD * Any condition that, in the opinion of the investigator, will preclude the participant from successfully or safely completing study procedures (i.e., dementia, severe depression, etc.) * People not able to give an informed consent. ``` ## Locations (4) - CHU Grenoble Alpes, Grenoble, Grenoble, France _(45.1787, 5.7148)_ - ELENA MORO — (CONTACT) — emoro@chu-grenoble.fr - Pierre PELISSIER — (CONTACT) — 0476769452 — ppelissier@chu-grenoble.fr - CHU Nantes Hôpital Laennec, Nantes, France _(47.2172, -1.5534)_ - Philippe DAMIER, Pr — (CONTACT) — 33 (0)2.40.16.52.12 — philippe.damier@chu-nantes.fr - Régis FRENAIS — (CONTACT) — 33 (0)2 44 76 87 57 — regis.frenais@chu-nantes.fr - CHU Rennes -Site Pontchaillou, Rennes, France _(48.1111, -1.6743)_ - Sophie DRAPIER, PH — (CONTACT) — +33 2 99 28 42 93 — Sophie.Drapier@chu-rennes.fr - Françoise KESTENS — (CONTACT) — 33 (0)2 99 28 93 34 — ide recherche neuro PPEV - Chu Toulouse, Toulouse, France _(43.6043, 1.4437)_ - Christine BREFEL-COURBON, PH — (CONTACT) — 33 (0)5 61 14 59 62 — christine.brefel-courbon@univ-tlse3.fr - Estelle HARROCH — (CONTACT) — +33 5 61 77 55 41 — harroch.e@chu-toulouse.fr ## Central Contacts - Elena MORO — (CONTACT) — 0476769452 — emoro@chu-grenoble.fr - PIERRE PELISSIER — (CONTACT) — 0476769459 — ppelissier@chu-grenoble.fr --- *Canonical: https://parkinsonspathways.com/trial/NCT06582212* *HTML version: https://parkinsonspathways.com/trial/NCT06582212* *Source data: https://clinicaltrials.gov/study/NCT06582212*